Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 19/05/2025

    How the Epstein-Barr virus promotes its spread in the body

    Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
  • Press release - 03/04/2025

    Heinz Maier-Leibnitz Prize for Lukas Bunse

    Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heinz-maier-leibnitz-prize-lukas-bunse
  • Press release - 17/03/2025

    New approach for T-cell immunotherapy against malignant brain tumors

    Researchers have developed a promising cellular immunotherapy for the treatment of glioblastomas: They equipped T cells with a receptor that recognizes a protein of the brain tumors that is responsible for the dangerous stem cell properties. The therapeutic T cells directed against this target structure were able to specifically destroy human brain tumors in laboratory experiments and in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-t-cell-immunotherapy-against-malignant-brain-tumors
  • Press release - 14/03/2025

    Tool identifies specific viruses to combat dangerous bacteria

    University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tool-identifies-specific-viruses-combat-dangerous-bacteria
  • Press release - 07/02/2025

    Multiple myeloma: When cancer cells break out of the bone marrow, a dangerous diversity arises

    A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-myeloma-when-cancer-cells-break-out-bone-marrow-dangerous-diversity-arises
  • Press release - 20/01/2025

    PAMSARC: New study at the NCT Heidelberg links research and clinical action

    Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pamsarc-new-study-nct-heidelberg-links-research-and-clinical-action
  • Press release - 15/01/2025

    Similarities discovered between vascular calcification and bone growth

    University of Tübingen research team observes biochemical process in living cells – indications of new approach to preventing heart attacks and strokes

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/similarities-discovered-between-vascular-calcification-and-bone-growth
  • Press release - 07/01/2025

    Researchers have a better understanding of how our cells dispose of waste while developing ways to control it

    A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-have-better-understanding-how-our-cells-dispose-waste-while-developing-ways-control-it
  • Press release - 03/01/2025

    New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells

    Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-against-metastatic-breast-cancer-mini-tumors-circulating-cancer-cells
  • Press release - 28/11/2024

    Molecular biology: New interdisciplinary Research Training Group investigates cellular regulation

    Cell division, cell differentiation, cell repair and cell death play fundamental roles in the human organism, its development, health and reproduction. Cellular transformation processes are governed by two regulatory mechanisms: chromatin modifications and cell signaling networks. The EpiSignal Research Training Group sheds light on the hitherto little-researched interplay between these two complex systems.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-biology-new-interdisciplinary-research-training-group-investigates-cellular-regulation
  • Press release - 01/10/2024

    Reporter Skin: In-vitro Skin Makes Cell Reaction to Test Substance Measurable in Real Time

    At the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, a three-dimensional skin model has now been set up for the first time that directly displays the skin's reaction to substances: The reporter skin. Thanks to the built-in reporter, the cellular response can be measured precisely and quickly – using a living model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reporter-skin-vitro-skin-makes-cell-reaction-test-substance-measurable-real-time
  • Press release - 05/09/2024

    Cohesion at the cellular level: flexible yet stable

    Research teams from the Universities of Konstanz and Potsdam are analyzing how proteins work together to enable our cells to both stick and move. The marker protein paxillin is at the centre of their interest.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cohesion-cellular-level-flexible-yet-stable
  • Press release - 22/08/2024

    Validated targets for personalized cancer immunotherapy

    Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
  • TWYCE GmbH - 10/07/2024 A micrograph shows how two T cells attack two tumour cells.

    Better immune response against prostate cancer thanks to new bispecific antibodies

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
  • Press release - 05/07/2024

    Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy

    The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
  • Press release - 04/07/2024

    Antibody can improve immune cell therapy against leukemia

    Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
  • Press release - 03/05/2024

    Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

    Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies
  • Press release - 14/03/2024

    Machine learning classifier accelerates the development of cellular immunotherapies

    Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-classifier-accelerates-development-cellular-immunotherapies
  • Press release - 22/02/2024

    A new approach to recording cellular activities

    In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities
  • Press release - 06/02/2024

    New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

    BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-t-finder-plattform-liefert-tiefe-einblicke-t-zell-antwort-auf-neuartigen-krebsimpfstoff
  • Press release - 18/01/2024

    Indicator for liver health status identified

    A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified
  • Press release - 04/01/2024

    Key player in viral heart inflammation discovered

    Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered
  • Press release - 06/11/2023

    Improving the efficacy of cancer immunotherapy with modified CAR-T cells

    CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
  • Press release - 26/10/2023

    Innovative research aims to improve wound healing and cancer therapy

    Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-forschung-soll-wundheilung-und-krebstherapie-verbessern
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
  • Press release - 28/08/2023

    Innovative computational approach helps design proteins for cancer treatment

    The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
  • Press release - 23/06/2023

    The molecular control centre of our protein factories

    Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
  • Predicting the success of cancer treatment - 20/06/2023 Graphical representation of the course of intestinal microbiome analysis in CAR-T cell therapy patients.

    Focusing on gut microbiome for CAR T-cell therapy

    Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/focusing-gut-microbiome-car-t-cell-therapy
  • Press release - 23/05/2023

    B cells promote liver cancer with dangerous dual strategy

    Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/b-cells-promote-liver-cancer-dangerous-dual-strategy
  • Immune complexes in COVID-19 - 01/03/2023 Zu sehen ist in einem Schema, wie einzelne Faktoren zu einer schweren Corona-Erkrankung führen können.

    Vicious circle of hyperinflammation

    Whether a person experiences only a mild malaise or a critical course of disease after a coronavirus infection apparently depends on the antigen-antibody complexes that form in our body. The discovery of these immune complexes set a group of researchers, headed up by Prof. Dr. Hartmut Hengel from the Freiburg University Medical Centre, on the trail of a vicious circle of constantly escalating inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vicious-circle-hyperinflammation
  • Press release - 31/01/2023

    ERC Consolidator Grants for Two Researchers from KIT

    In the 2022 allocation round for the award of the prestigious Consolidator Grants of the European Research Council, researchers of Karlsruhe Institute of Technology (KIT) have been successful. For their projects in the fields of photovoltaics and medical sensor technology, physicist Ulrich W. Paetzold and chemist Frank Biedermann will receive approximately two million euros over the next five years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-fuer-zwei-forscher-des-kit
  • Press release - 11/01/2023

    Newly discovered surface structures may affect immune function

    Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
  • Press release - 20/12/2022

    Enzyme inhibition promotes bone formation and curbs the development of bone metastases

    In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-inhibition-promotes-bone-formation-and-curbs-development-bone-metastases
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
  • Press release - 24/10/2022

    How tumors suppress the development of metastases

    Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-tumoren-die-entstehung-von-metastasen-unterdruecken
  • Press release - 19/10/2022

    Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

    Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
  • Press release - 19/10/2022

    Molecular structure of one of the most important receptors in the immune system unraveled

    Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
  • Press release - 05/10/2022

    Second Stem Cell Type Discovered in Mouse Brain

    In the brain of adult mammals neural stem cells ensure that new nerve cells, i.e. neurons, are constantly formed. This process, known as adult neurogenesis, helps mice maintain their sense of smell. A research team led by Dr Francesca Ciccolini at the Interdisciplinary Center for Neurosciences (IZN) of Heidelberg University recently discovered a second stem cell population in the mouse brain.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zweiter-stammzelltyp-im-maeusehirn-entdeckt
  • Press release - 12/05/2022

    New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses

    While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
  • SolidCAR-T project - 15/03/2022 Drawing illustrating the individual steps inside a mini-factory, starting with the collection of T lymphocytes, the preparation, processing and post-processing of the CAR T cells and ending with the treatment of the patient.

    Modular ‘mini-factories’ for decentralised production of CAR T cells

    Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
  • Press release - 14/03/2022

    Do gut bacteria influence treatment success of CAR-T cell therapies?

    Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
  • Press release - 07/12/2021

    New approach developed to predict response of immunotherapies in lung cancer

    At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
  • Press release - 15/11/2021

    Using T cell to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Booster for neutrophil granulocytes - 27/10/2021 acetat-aktivierung_Bearbeitet.jpg

    Acetate supports immune cells to fight against sepsis

    Blood poisoning is the most dangerous complication of bacterial infections and often leads to death. Researchers at the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen have now identified acetate as a potent agent for stimulating innate immune system cells, supporting their ability to destroy bacteria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/acetate-supports-immune-cells-fight-against-sepsis
  • Press release - 21/09/2021

    Antibiotic levels measurable in breath for first time

    A team of engineers and biotechnologists at the University of Freiburg has for the first time shown in mammals that the concentration of antibiotics in the body can be determined using breath samples. The breath measurements also corresponded to the antibiotic concentrations in the blood. The team’s biosensor – a multiplex chip – will in future enable personalized dosing of medicines against infectious diseases on-site.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibiotic-levels-measurable-breath-first-time
  • Press release - 02/09/2021

    Award-winning science: Cancer-promoting metabolic pathways as targets of new therapies

    Christiane Opitz, scientist at the German Cancer Research Center, is being awarded this year's Ita Askonas Prize of the European Federation of Immunological Societies. Opitz has discovered how tumor cells use certain metabolites to protect themselves against the immune system. Her research findings may provide important clues for the development of new therapeutic concepts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-winning-science-cancer-promoting-metabolic-pathways-targets-new-therapies
  • Article - 31/05/2021 Das Foto zeigt einen Gewebeschnitt, auf dem immunhistologisch angefärbte angefärbte Pankreaskarzinomzellen zu sehen sind.

    Tracking down tumour-associated pain in pancreatic cancer

    Pancreatic cancer comes along quietly: unnoticed for a long time, it often triggers excruciating pain as the tumour progresses. This pain is associated with cancer cells invading pancreatic nerves. Dr. Michael Hirth from Mannheim University Hospital has shed some light on the complex communication between cancer cells and nerve cells. His findings could eventually be used for personalised pain therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tracking-down-tumour-associated-pain-pancreatic-cancer
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Press release - 14/04/2021

    Engineering T cells for cancer therapy efficiently and safely

    Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/engineering-t-cells-cancer-therapy-efficiently-and-safely
  • Press release - 23/03/2021

    CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b1351-variant-south-african-variant-precli

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search